Serum Vascular Endothelial Growth Factor Level in Patients With Hematological Malignancies

Erdem, Fuat; Gündoğdu, Mehmet; Kızıltunç, Ahmet

doi:10.29333/ejgm/82390

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… shows the absorption spectrum of human serum. The absorption features are consistent with the literature [ 18 ], while the dominant absorption peak at 280 nm is mainly due to the proteins in the serum [ 5 , 19 ]. Figure 1(b) shows the DL spectrum of human serum, which exhibits similar emission characteristics comparing to previously reported fluorescence spectra [ 18 , 20 ].…”

Section: Resultssupporting

confidence: 89%

“…To diagnose leukemia, numerous methods have been employed to acquire information about the changes of serum components that serve as disease markers. For example, serum levels of vascular endothelial growth factor of the patients with hematological malignancies were examined by enzyme-linked immunosorbent assay method [ 5 ]. The concentrations of trace and major elements in serum of patients with chronic myelogenous leukemia were determined by using total reflection X-ray fluorescence with synchrotron radiation [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Spectral discrimination between normal and leukemic human sera using delayed luminescence

Chen¹,

Zhang²,

Zhang³

et al. 2012

Biomed. Opt. Express

View full text Add to dashboard Cite

In this work, photoinduced delayed luminescence (DL) was used to distinguish serum samples of patients with acute lymphoblastic leukemia from those of healthy volunteers. DL decay kinetics of human serum samples was measured using a homebuilt ultraweak luminescence detection system. It was found a significant difference in the weight distribution of the decay rate between normal and leukemic serum samples. A comparison of the DL kinetics parameters including the initial intensity, the peak decay rate, and the peak weight value was used in making discrimination between normal and leukemic human sera. Results in this work contribute to the development of a novel optical method for the early diagnosis of leukemia.

show abstract

Section: Resultssupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Spectral discrimination between normal and leukemic human sera using delayed luminescence

Chen¹,

Zhang²,

Zhang³

et al. 2012

Biomed. Opt. Express

View full text Add to dashboard Cite

show abstract

“…Increased serum VEGF level was observed in cases of AML as compared to ALL which was seen in the majority of studies performed by various authors. 12,16,21 However, in our study levels of serum VEGF were slightly higher in ALL as compared to AML. This might be due to inclusion of cases of CML in blast crisis of lymphoid origin as these cases showed very high levels of serum VEGF (Table 4).…”

Section: Comparison Of Serum Vegf Concentration In Aml All and Contro...contrasting

confidence: 55%

“…Of the various methods to assess angiogenesis, micro vessel density has been studied extensively in various tumors. 16 The reason why these parameters should be studied is to yield important information on the relationship to other clinico-pathological tumor characteristics and help testing of anti-angiogenic therapies.…”

Section: Discussionmentioning

confidence: 99%

A study of bone marrow angiogenesis and its correlation with serum vascular endothelial growth factor levels in acute leukaemia

et al. 2022

View full text Add to dashboard Cite

Background: Angiogenesis, which is the development of new capillaries from existing blood vessels, occurs in both the developing embryo and postnatal life. The growth of solid tumours requires the development of micro vessels; therefore, tumour expansion correlates with the extent of angiogenesis.Methods: A prospective study was conducted on bone marrow trephine biopsies of 40 new cases of acute leukaemia diagnosed on complete blood count, bone marrow aspiration examination, and flow cytometry, including 20 control cases. Micro sections were stained with immuno-histochemical stains using monoclonal antibodies to CD31, CD34 and vWF. Micro vessel density was analysed at a 400× using automated image analyser by two investigators independently. Data were calculated, tabulated and statistically analysed using statistical package for the social sciences (SPSS) statistical program version 18.Results: A total of 1522 micro vessels were analysed using CD31 including 802 in acute myeloid leukaemia (AML), 512 in acute lymphocytic leukemia (ALL) and 208 in the control group. The bone marrow microvessel density (MVD) in acute myeloid leukaemia using CD31, CD34 and Von Willebrand factor (VWF) was 70.83±20.76, 66.48±18.99 and 60.32±18.75 respectively while MVD in acute lymphoblastic leukaemia was 62.74±21.09, 70.58±22.46 and 51.22±21.13 respectively. The study revealed significant difference between AML, ALL and normal bone marrow cases by using CD31, CD34 and vWF antibody. Serum vascular endothelial growth factor (VEGF) concentration in AML, ALL and control group was 163.74±119.03, 168.23±154.22 and 43.45±9.14 respectively.Conclusions: Higher micro vessel density was observed in acute leukaemia. Present findings suggested the potential significance of characteristics of micro vessel density as potential prognostic marker as well as its application in improved selection of patients for anti-angiogenic and other treatments.

show abstract

“…One study showed that total serum VEGF in AML patients was significantly lower than that in healthy controls, possibly due to thrombocytopenia in AML patients [19]. Several studies have shown higher levels of VEGF in AML patients than healthy controls [20][21][22][23][24]. Besides, Aref et al [25,26], Aguayo et al [16,27], and Wang et al [28,29] all showed elevated level of VEGF in AML patients compared to normal control.…”

Section: Introductionmentioning

confidence: 99%

Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis

Song

Wang

2020

Syst Rev

View full text Add to dashboard Cite

Background: Vascular endothelial growth factor (VEGF) is one of the angiogenesis regulators, which plays an important role in tumor angiogenesis and tumor progression. Current studies have found that VEGF plays an important role in hematologic diseases including acute myeloid leukemia (AML). However, the circulating levels of VEGF in AML were still controversial among published studies. Methods: Three databases including PubMed, EMBASE, and Cochrane Library databases were searched up to February 2020. All articles included in the meta-analysis met our inclusion and exclusion criteria. Studies will be screened and data extracted by two independent investigators. The Newcastle-Ottawa Scale (NOS) and the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool were applied to evaluate the quality of the included studies. A random-effects model was applied to pool the standardized mean difference (SMD). Heterogeneity test was performed by the Q statistic and quantified using I 2. All statistical analysis was conducted in Stata 12.0 software. Results: Fourteen case-control studies were finally included in this systematic review and meta-analysis. Heterogeneity was high in our included studies (I 2 = 91.1%, P < 0.001). Sensitivity analysis showed no significant change when any one study was excluded using random-effect methods (P > 0.05). Egger's linear regression test showed that no publication bias existed (P > 0.05). Patients with AML, mainly those newly diagnosed and untreated, have higher VEGF levels (SMD = 0.85, 95% CI 0.28-1.42). Moreover, AML patients in n ≥ 40 group, plasma group, Asia and Africa group, and age ≥ 45 group had higher circulating VEGF levels (all P < 0.05). Conclusions: Compared to healthy controls, our meta-analysis shows a significantly higher level of circulating VEGF in AML patients, and it is associated with sample size, sample type, region, and age.

show abstract

Serum Vascular Endothelial Growth Factor Level in Patients With Hematological Malignancies

Cited by 4 publications

References 24 publications

Spectral discrimination between normal and leukemic human sera using delayed luminescence

Spectral discrimination between normal and leukemic human sera using delayed luminescence

A study of bone marrow angiogenesis and its correlation with serum vascular endothelial growth factor levels in acute leukaemia

Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis

Contact Info

Product

Resources

About